David A. Siegel Atea Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

$43.8 Billion
Q2 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 612,200 shares of AVIR stock, worth $2.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

612,200

Previous 577,400 6.03%

Holding current value

$2.06 Million

Previous $2.33 Million 13.12%

% of portfolio

0.0%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.31 - $4.04 $115,188 - $140,592	34,800 Added 6.03%	612,200 $2.03 Million
Q1 2024 May 15, 2024	BUY	$3.09 - $4.56 $798,147 - $1.18 Million	258,300 Added 80.95%	577,400 $2.33 Million
Q4 2023 Feb 14, 2024	BUY	$2.8 - $3.35 $316,960 - $379,220	113,200 Added 54.98%	319,100 $973,000
Q3 2023 Nov 14, 2023	BUY	$3.0 - $3.79 $477,900 - $603,747	159,300 Added 341.85%	205,900 $617,000
Q2 2023 Aug 14, 2023	BUY	$3.21 - $5.06 $149,586 - $235,795	46,600 New	46,600 $174,000
Q2 2022 Aug 15, 2022	SELL	$5.33 - $8.18 $402,415 - $617,590	-75,500 Reduced 77.6%	21,800 $155,000
Q1 2022 May 16, 2022	BUY	$5.5 - $9.19 $226,050 - $377,709	41,100 Added 73.13%	97,300 $703,000
Q4 2021 Feb 14, 2022	BUY	$7.67 - $44.59 $431,054 - $2.51 Million	56,200 New	56,200 $502,000
Q3 2021 Nov 15, 2021	SELL	$21.33 - $35.06 $296,487 - $487,334	-13,900 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$19.22 - $59.08 $267,158 - $821,212	13,900 New	13,900 $299,000

Others Institutions Holding AVIR

# of Institutions

113

Shares Held

51.8M

Call Options Held

71.8K

Put Options Held

318K

View Full List

About Atea Pharmaceuticals, Inc.

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $280M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

More about AVIR

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account